INVESTMENT OPPORTUNITY
The global healthcare industry benefits from strong long-term growth trends, driven by advanced scientific innovation in treating disease and demographic aging.
The US birthrate increased by 20% in the first year after the end of World War II. By 1965, the 76.4 million Baby Boomers represented nearly 40% of the US population. By 2030, every person in this demographic group will be 65 or older. By 2029 the US Government will spend over half of its healthcare budget supporting older adults.
The rapid emergence of life-saving, innovative medical technologies is being driven by favorable government initiatives. US government activities aim to streamline the medication regulatory pathway, standardizing clinical studies, enhancing reimbursement policies, and expediting the product approval process, all of which will provide the industry with lucrative growth potential.
These trends have led to a steady increase in healthcare spending in the industrialized world, led by the US, which now spends over 18% of its GDP on healthcare.
We believe that the strong growth of the healthcare industry, combined with its scale and complexity, creates many profitable and overlooked investment opportunities.
The US birthrate increased by 20% in the first year after the end of World War II. By 1965, the 76.4 million Baby Boomers represented nearly 40% of the US population. By 2030, every person in this demographic group will be 65 or older. By 2029 the US Government will spend over half of its healthcare budget supporting older adults.
The rapid emergence of life-saving, innovative medical technologies is being driven by favorable government initiatives. US government activities aim to streamline the medication regulatory pathway, standardizing clinical studies, enhancing reimbursement policies, and expediting the product approval process, all of which will provide the industry with lucrative growth potential.
These trends have led to a steady increase in healthcare spending in the industrialized world, led by the US, which now spends over 18% of its GDP on healthcare.
We believe that the strong growth of the healthcare industry, combined with its scale and complexity, creates many profitable and overlooked investment opportunities.
The birthrate in the United States increased by 20% during the first year since the end of World War II. By 1965, the 76.4 million Baby Boomer generation made up nearly 40% of the US population. Every person in this demographic will be 65 or older by 2030. By 2029 the US Government will spend over half of its healthcare budget to support older adults.
The rapid emergence of life-saving, innovative medical technologies is being driven by favorable government initiatives. US government activities aim to streamline the medication regulatory pathway, standardizing clinical studies, enhancing reimbursement policies, and expediting the product approval process, all of which will provide the industry with lucrative growth potential.
These trends have caused a steady increase in healthcare spending in the industrialized world, led by the US, which now spends over 18% of its GDP on healthcare.
We believe that the strong growth of the healthcare industry, combined with its scale and complexity, creates many profitable and overlooked investment opportunities.
We believe that the strong growth of the healthcare industry, combined with its scale and complexity, creates many profitable and overlooked investment opportunities.
INVESTMENT STRATEGY
The global biotechnology market will continue to demonstrate significant growth of 12.8% CAGR over the next several years, from USD 1,224.31 billion in 2022 to USD 3,210.71 billion in 2030. The Fund's primary objective is to identify unique or mispriced investment opportunities in this sector that are underpinned by unmet medical needs, to reduce risk and to enhance clients' capital by making investment decisions based on unique and thorough fundamental research while consistently demonstrating positive Alpha.
Prime Biotech Investments Fund invests exclusively in publicly traded life science companies (biotechnology, pharmaceuticals, diagnostics) based in the United States, Canada, Europe and Australia. Our investments are value-driven and scientifically validated. We select fundamentally undervalued companies with IP-protected products that are either clinically proven or undergoing clinical trials. We focus on companies with strong technologies working to make a difference in areas of unmet medical need.
We employ a market-neutral, long/short strategy, primarily hedging market risk by taking a short position in ETF funds tied to the Nasdaq Biotechnology Index. In its normalized state, the portfolio generally targets gross exposure / net exposure ratios of 150-200% / 0-50% of NAV. Risks are managed by portfolio diversification with limits on individual investments, therapeutic areas, technologies and stages of development. At the asset level, we select companies with diversified portfolios, generally avoiding all-or-nothing scenarios. Where appropriate, we utilize options to improve the reward-to-risk ratio of our investments.
Prime Biotech Investments Fund invests exclusively in publicly traded life science companies (biotechnology, pharmaceuticals, diagnostics) based in the United States, Canada, Europe and Australia. Our investments are value-driven and scientifically validated. We select fundamentally undervalued companies with IP-protected products that are either clinically proven or undergoing clinical trials. We focus on companies with strong technologies working to make a difference in areas of unmet medical need.
We employ a market-neutral, long/short strategy, primarily hedging market risk by taking a short position in ETF funds tied to the Nasdaq Biotechnology Index. In its normalized state, the portfolio generally targets gross exposure / net exposure ratios of 150-200% / 0-50% of NAV. Risks are managed by portfolio diversification with limits on individual investments, therapeutic areas, technologies and stages of development. At the asset level, we select companies with diversified portfolios, generally avoiding all-or-nothing scenarios. Where appropriate, we utilize options to improve the reward-to-risk ratio of our investments.
We seek out portfolio candidates with novel approaches to drug development and long-term use in chronic disease management, pursuing cutting edge science and demonstrating sound business fundamentals.
Our main goal is to identify unique or mispriced investment opportunities in this sector, reduce risk and increase clients’ capital by making investment decisions based on unique and thorough fundamental research while consistently demonstrating positive Alpha. Our investments are value-driven and scientifically validated.
INVESTMENT TEAM
Vladislav Shayman
Founder and Managing Partner
Overall responsibility for fund management and investment decisions.
10+ years of experience successfully investing into small- and mid-cap biotechnology companies.
Formerly with Takeda Pharmaceuticals in a market access role.
Formerly Board Member of European immunotherapy company Genetic Immunity.
Educated at University of Wisconsin – Madison (BA) and Central European University (MBA, LL.M.).
10+ years of experience successfully investing into small- and mid-cap biotechnology companies.
Formerly with Takeda Pharmaceuticals in a market access role.
Formerly Board Member of European immunotherapy company Genetic Immunity.
Educated at University of Wisconsin – Madison (BA) and Central European University (MBA, LL.M.).
Dmitry Gurevich
Head of Analytics
Responsible for qualitative and quantitative analysis of new investment opportunities and portfolio companies.
20+ years of experience in private equity and hedge funds in various roles from analyst to director.
Formerly responsible for investing strategy and analysis at HTI Group and IGI Capital Management.
Formerly board member of several fund portfolio companies, as well as investment committee member.
Formerly a researcher with the Department of Neuroscience at the University of Pennsylvania Medical School.
Educated at MIPT (BS), Case Western Reserve University and Thomas Jefferson University.
20+ years of experience in private equity and hedge funds in various roles from analyst to director.
Formerly responsible for investing strategy and analysis at HTI Group and IGI Capital Management.
Formerly board member of several fund portfolio companies, as well as investment committee member.
Formerly a researcher with the Department of Neuroscience at the University of Pennsylvania Medical School.
Educated at MIPT (BS), Case Western Reserve University and Thomas Jefferson University.
Dr. Marina Granovskaya
Head of Science
Responsible for scientific validation of all portfolio companies.
Expertise in molecular and systems medicine, biochemistry, epigenetics, pharmacogenomics, oncology and onco-immunology, personalized –omics technologies, complex diseases and translational medicine.
15+ years’ experience conducting high-level practical and theoretical pharmacological research.
Held various senior scientific roles with Roche, Merck Serono, Ferring and AstraZeneca.
Adjunct Associate Professor at Systems Biology Ireland.
Educated at Yale (MPhil), EMBL-Heidelberg (PhD).
Expertise in molecular and systems medicine, biochemistry, epigenetics, pharmacogenomics, oncology and onco-immunology, personalized –omics technologies, complex diseases and translational medicine.
15+ years’ experience conducting high-level practical and theoretical pharmacological research.
Held various senior scientific roles with Roche, Merck Serono, Ferring and AstraZeneca.
Adjunct Associate Professor at Systems Biology Ireland.
Educated at Yale (MPhil), EMBL-Heidelberg (PhD).
Rita Goldman
Head of Administration
Responsible for all fund operations and administration.
10+ years of experience as Executive Assistant for various UHNWI and C-suite organization leaders.
10+ years of experience in project management roles across Europe and Asia.
Formerly Project Coordinator with the European Jewish Congress.
Almost two decades of experience across a diverse array of industries such as healthcare, real estate, technology, industrials, logistics and retail.
10+ years of experience as Executive Assistant for various UHNWI and C-suite organization leaders.
10+ years of experience in project management roles across Europe and Asia.
Formerly Project Coordinator with the European Jewish Congress.
Almost two decades of experience across a diverse array of industries such as healthcare, real estate, technology, industrials, logistics and retail.
Nikola Tesla
Nikola Tesla was a Serbian American inventor, electrical engineer, mechanical engineer, physicist, and futurist best known for his contributions to the design of the modern alternating current (AC) electricity supply system.
Website Privacy Policy
The privacy practices of this Privacy Policy apply to our services available under the domain and subdomains of www.prime-biotech-investments.com (the "Site"). We recognize that privacy is important to our users, so we design and operate our Site with the protection of your privacy in mind. This Privacy Policy outlines the types of personal information we may gather when you visit our Site or use our services, as well as some of the steps we take to safeguard it. Please read this Privacy Policy to learn more about the ways in which we protect, use and disclose your personal information. By visiting the Site, you agree to be bound by the terms and conditions of this Privacy Policy. If you do not agree please do not use or access the Site.
By accepting the Privacy Policy, you expressly consent to our use and disclosure of your personal information in accordance with this Privacy Policy. This Privacy Policy is effective upon acceptance for new users, and is otherwise effective on April 1, 2018, for all users.
Overview
We have adopted general policies and procedures concerning confidentiality, proprietary data and privacy of client personal information, and the information we gather over the Site is protected by those policies and procedures. Generally, we collect non-public personal information about our clients and investors from the following sources:
Collection of Information
In general, you can browse the Site without telling us who you are or revealing any personal information about yourself.
We automatically track certain information that your browser makes available whenever you visit a website. This information includes your Internet Protocol address, browser type, browser language and one or more files that may uniquely identify your browser. We may use this information to do internal research on our users' demographics, interests and behavior to better understand, protect and serve you and our clients. This information may include the URL that you just came from (whether this URL is on the Site or not), which URL you next go to (whether this URL is on the Site or not), your computer browser information and your IP address. We use this information to operate, develop and improve our services.
We also may use data collection devices such as "cookies" on certain pages of the Site to help analyze our web page flow, measure effectiveness and promote trust and safety. "Cookies" are small files placed on your hard drive that assist us in providing our services. We offer certain features that are only available through the use of a "cookie". Cookies can also help us provide information that is targeted to your interests. Most cookies are "session cookies" meaning that they are automatically deleted from your hard drive at the end of a session. You are always free to decline our cookies if your browser permits, although in that case you may not be able to use certain features on the Site. We use cookies to better understand how people interact with us.
If you use the “Contact Us” form on this Site, you must provide to us your name and email address.
Use and Disclosure of Information
We use the information we collect from our browser and data collection devices such as cookies to improve our operations and facilitate the services you request. We may use information collected from you to measure interest and customize your experience. We may use the data to determine whether you are an accredited investor and have sufficient sophistication, investment experience and wealth to receive information about certain investment options.
You agree that we may use personal information about you to analyze Site usage, improve our content and product offerings and customize the Site’s content, layout, and services. These uses improve the Site and better tailor it to meet your needs, so as to provide you with a smooth, efficient, safe and customized experience while using the Site.
In connection with providing our services, it also may be necessary for us to share information with other third parties to help us process transactions relating to your account, including, but not limited to, asset transfers from a financial institution and processing or administering investment transactions and portfolios. In certain instances, we may contract with third parties that are not affiliated with us to perform services for us, and, if necessary, we may disclose information about you to those third parties solely for the purpose of carrying out their assigned responsibilities. In those circumstances, we require such third parties to treat your private information with the same degree of confidentiality that we do. In some instances, the third-party service provider may collect information directly from you. In these cases, you will be notified of the involvement of the service provider, and all additional information you provide them and their additional uses will be strictly up to you. If you provide additional information to a service provider directly, their use of your personal information is governed by their applicable privacy policy.
We may also share information about you if we believe that disclosure is required under law. For example, we may need to disclose information in response to a subpoena or to cooperate with regulatory or law enforcement authorities.
We cannot ensure that all of your private communications and other personal information will never be disclosed in ways not otherwise described in this Privacy Policy. By way of example (without limiting the foregoing), we may be forced to disclose personal information to the government or third parties under certain circumstances, third parties may unlawfully intercept or access transmissions or private communications, or service providers may abuse or misuse your personal information that they collect from the Site. Therefore, although we use industry standard practices to protect your privacy, we do not promise, and you should not expect, that your personal information or private communications will always remain private.
Control of Your Personal Information
You can review and change the information you submit to us by contacting us at info@prime-biotech-investments.com. You can change your email address, contact information, financial information, and other personal information
Upon your request, we will remove your contact information and financial information from our active databases. To make this request, email info@prime-biotech-investments.com
We will retain in our files the personal information you have asked us to remove from our active databases to prevent fraud, resolve disputes, troubleshoot problems, assist with any investigations, enforce our Terms of Use and comply with legal requirements. Therefore, you should not expect that your personal information will be completely removed from our databases in response to your requests. However, such personal information will only be available to select employees, service providers and governmental persons or entities.
Security
Your information is stored on our servers. We use procedural and technical safeguards to protect your personal information against loss or theft as well as unauthorized access and disclosure to protect your privacy. We treat data as an asset that must be protected against loss and unauthorized access. We employ security techniques to protect such data from unauthorized access by users inside and outside the company. However, "perfect security" does not exist on the Internet.
For example, it is possible that a third party will circumvent our security, and we do not guarantee that our security measures will successfully prevent third parties from accessing the information we collect. If there is a security breach involving your information, we will make any legally required disclosures to you, consistent with the legitimate interests of law enforcement, or any measures necessary to determine the scope of the breach and restore the reasonable integrity of the data system.
No Securities Offering or Investment Advice
The information on the Site is intended to enable investors to understand the nature of the Firm’s financial advisory services. It is not intended as and does not constitute investment advice or legal or tax advice or an offer to sell any securities to any person or a solicitation of any person of any offer to purchase any securities. The information in the Site should not be construed as any endorsement, recommendation or sponsorship of any company or security by the Fund.
You acknowledge that any requests by you for information are unsolicited and any information the Fund provides is neither investment advice to you or the formation of an investment advisory relationship, or any other client relationship.
Children
Children (persons under the age of 18) are not eligible to use the Site and, therefore, we do not knowingly collect any personal information from persons under the age of 18.
Conditions Of Use
If you choose to visit the Site, your visit and any dispute over privacy is subject to this Privacy Policy, including limitations on damages and application of the law of the State of California. If you have any concern about privacy, please send a thorough description to info@prime-biotech-investments.com
Changes to this policy
Please note this Privacy Policy may change from time to time. We may amend this Privacy Policy at any time by posting the amended terms on the Site. All amended terms shall automatically be effective 30 days after they are initially posted on the Site. Your continued use of the Site constitutes your agreement to this Privacy Policy and any changes to it. If we make any material changes, we will post a prominent notice on the Site stating that this Privacy Policy has changed. If you do not agree with this Privacy Policy or any changes to it, please do not use or access the Site.
If you have any additional questions, please feel free to contact us any time at info@prime-biotech-investments.com
By accepting the Privacy Policy, you expressly consent to our use and disclosure of your personal information in accordance with this Privacy Policy. This Privacy Policy is effective upon acceptance for new users, and is otherwise effective on April 1, 2018, for all users.
Overview
We have adopted general policies and procedures concerning confidentiality, proprietary data and privacy of client personal information, and the information we gather over the Site is protected by those policies and procedures. Generally, we collect non-public personal information about our clients and investors from the following sources:
- Information received from clients or investors on applications or other forms, including the information we collect on the Site, and
- Information about clients’ or investors’ transactions with us, our affiliates or others.
- We do not disclose any non-public personal information about our clients or investors or former clients or investors to anyone, except as permitted by law. In addition, we share non-public personal information with certain service providers, to the extent permitted by law, and we require those service providers to keep the non-public information confidential.
- We restrict access to non-public personal information about our clients and investors to employees and service providers who need to know that information to provide services to our clients.
- We maintain physical, electronic and procedural safeguards that comply with federal standards to guard clients’ and investors’ personal information.
Collection of Information
In general, you can browse the Site without telling us who you are or revealing any personal information about yourself.
We automatically track certain information that your browser makes available whenever you visit a website. This information includes your Internet Protocol address, browser type, browser language and one or more files that may uniquely identify your browser. We may use this information to do internal research on our users' demographics, interests and behavior to better understand, protect and serve you and our clients. This information may include the URL that you just came from (whether this URL is on the Site or not), which URL you next go to (whether this URL is on the Site or not), your computer browser information and your IP address. We use this information to operate, develop and improve our services.
We also may use data collection devices such as "cookies" on certain pages of the Site to help analyze our web page flow, measure effectiveness and promote trust and safety. "Cookies" are small files placed on your hard drive that assist us in providing our services. We offer certain features that are only available through the use of a "cookie". Cookies can also help us provide information that is targeted to your interests. Most cookies are "session cookies" meaning that they are automatically deleted from your hard drive at the end of a session. You are always free to decline our cookies if your browser permits, although in that case you may not be able to use certain features on the Site. We use cookies to better understand how people interact with us.
If you use the “Contact Us” form on this Site, you must provide to us your name and email address.
Use and Disclosure of Information
We use the information we collect from our browser and data collection devices such as cookies to improve our operations and facilitate the services you request. We may use information collected from you to measure interest and customize your experience. We may use the data to determine whether you are an accredited investor and have sufficient sophistication, investment experience and wealth to receive information about certain investment options.
You agree that we may use personal information about you to analyze Site usage, improve our content and product offerings and customize the Site’s content, layout, and services. These uses improve the Site and better tailor it to meet your needs, so as to provide you with a smooth, efficient, safe and customized experience while using the Site.
In connection with providing our services, it also may be necessary for us to share information with other third parties to help us process transactions relating to your account, including, but not limited to, asset transfers from a financial institution and processing or administering investment transactions and portfolios. In certain instances, we may contract with third parties that are not affiliated with us to perform services for us, and, if necessary, we may disclose information about you to those third parties solely for the purpose of carrying out their assigned responsibilities. In those circumstances, we require such third parties to treat your private information with the same degree of confidentiality that we do. In some instances, the third-party service provider may collect information directly from you. In these cases, you will be notified of the involvement of the service provider, and all additional information you provide them and their additional uses will be strictly up to you. If you provide additional information to a service provider directly, their use of your personal information is governed by their applicable privacy policy.
We may also share information about you if we believe that disclosure is required under law. For example, we may need to disclose information in response to a subpoena or to cooperate with regulatory or law enforcement authorities.
We cannot ensure that all of your private communications and other personal information will never be disclosed in ways not otherwise described in this Privacy Policy. By way of example (without limiting the foregoing), we may be forced to disclose personal information to the government or third parties under certain circumstances, third parties may unlawfully intercept or access transmissions or private communications, or service providers may abuse or misuse your personal information that they collect from the Site. Therefore, although we use industry standard practices to protect your privacy, we do not promise, and you should not expect, that your personal information or private communications will always remain private.
Control of Your Personal Information
You can review and change the information you submit to us by contacting us at info@prime-biotech-investments.com. You can change your email address, contact information, financial information, and other personal information
Upon your request, we will remove your contact information and financial information from our active databases. To make this request, email info@prime-biotech-investments.com
We will retain in our files the personal information you have asked us to remove from our active databases to prevent fraud, resolve disputes, troubleshoot problems, assist with any investigations, enforce our Terms of Use and comply with legal requirements. Therefore, you should not expect that your personal information will be completely removed from our databases in response to your requests. However, such personal information will only be available to select employees, service providers and governmental persons or entities.
Security
Your information is stored on our servers. We use procedural and technical safeguards to protect your personal information against loss or theft as well as unauthorized access and disclosure to protect your privacy. We treat data as an asset that must be protected against loss and unauthorized access. We employ security techniques to protect such data from unauthorized access by users inside and outside the company. However, "perfect security" does not exist on the Internet.
For example, it is possible that a third party will circumvent our security, and we do not guarantee that our security measures will successfully prevent third parties from accessing the information we collect. If there is a security breach involving your information, we will make any legally required disclosures to you, consistent with the legitimate interests of law enforcement, or any measures necessary to determine the scope of the breach and restore the reasonable integrity of the data system.
No Securities Offering or Investment Advice
The information on the Site is intended to enable investors to understand the nature of the Firm’s financial advisory services. It is not intended as and does not constitute investment advice or legal or tax advice or an offer to sell any securities to any person or a solicitation of any person of any offer to purchase any securities. The information in the Site should not be construed as any endorsement, recommendation or sponsorship of any company or security by the Fund.
You acknowledge that any requests by you for information are unsolicited and any information the Fund provides is neither investment advice to you or the formation of an investment advisory relationship, or any other client relationship.
Children
Children (persons under the age of 18) are not eligible to use the Site and, therefore, we do not knowingly collect any personal information from persons under the age of 18.
Conditions Of Use
If you choose to visit the Site, your visit and any dispute over privacy is subject to this Privacy Policy, including limitations on damages and application of the law of the State of California. If you have any concern about privacy, please send a thorough description to info@prime-biotech-investments.com
Changes to this policy
Please note this Privacy Policy may change from time to time. We may amend this Privacy Policy at any time by posting the amended terms on the Site. All amended terms shall automatically be effective 30 days after they are initially posted on the Site. Your continued use of the Site constitutes your agreement to this Privacy Policy and any changes to it. If we make any material changes, we will post a prominent notice on the Site stating that this Privacy Policy has changed. If you do not agree with this Privacy Policy or any changes to it, please do not use or access the Site.
If you have any additional questions, please feel free to contact us any time at info@prime-biotech-investments.com
Оставить заявку
Укажите свои контактные данные для того, чтобы мы могли связаться с вами
You agree to the Privacy Policy by clicking the "Submit" button.